Research advances in novel PET/CT tracers for the diagnosis and treatment of renal cell carcinoma
10.3969/j.issn.1009-8291.2025.11.007
- VernacularTitle:用于肾细胞癌诊治的新型PET/CT示踪剂研究进展
- Author:
Xinji YANG
1
;
Zhanyi ZHANG
1
;
Xiaofei HOU
1
;
Shudong ZHANG
1
Author Information
1. 北京大学第三医院泌尿外科,北京 100191
- Publication Type:Journal Article
- Keywords:
renal cell carcinoma;
positron emission computed tomography;
computed tomography;
tracer;
18F-Fluorodeoxyglucose;
carbonic anhydrase Ⅸ;
prostate-specific membrane antigen;
fibroblast activation protein;
somatostatin receptor;
C-methionine
- From:
Journal of Modern Urology
2025;30(11):947-954
- CountryChina
- Language:Chinese
-
Abstract:
Renal cell carcinoma(RCC)is a highly aggressive malignant tumor,for which traditional 18F-FDG positron emission computed tomography/computed tomography(PET/CT)exhibits insufficient sensitivity in diagnosing primary lesions.This article reviews the recent advances in novel PET/CT tracers for the diagnosis and treatment of RCC,focusing on tracers targeting carbonic anhydrase Ⅸ(CAⅨ),prostate-specific membrane antigen(PSMA),fibroblast activation protein(FAP),somatostatin receptor(SSTR),and C-methionine(c-MET).This article aims to provide reference for the early diagnosis and optimization of treatment strategies for RCC,so as to drive innovations in the field of oncologic imaging.These novel tracers demonstrate significant advantages in improving the sensitivity and specificity of detecting primary and metastatic RCC lesions,as well as in assessing treatment response,thereby addressing the limitations of traditional 18F-FDG PET/CT.Although these novel PET/CT tracers show great potential in the diagnosis and treatment of RCC,their efficacy and safety require further validation through large-scale trials.In the future,the development of multi-target tracers combined with artificial intelligence is expected to achieve precise diagnosis and individualized treatment of RCC.
